Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Functional genomics study on Non Alcoholic fatty liver disease (NAFLD) - part III (Study ST000680)

C18 NEGATIVE ION MODE (Analysis AN001046)

Metabolite	Structure	F1	F2	F3	F4	F5	F6
PC 44:2; [M-Ac-H]-@8.78	ME189164	1.41	0.94	1.01	1.16	0.50	0.96
PG 44:11; [M-H]-@5.02	ME189225	1.93	0.78	1.04	0.87	0.51	0.80
PG 42:10; [M-H]-@4.76	ME189220	1.95	0.84	0.74	0.91	0.58	0.92
PG 44:12; [M-H]-@4.61	ME189226	1.86	0.88	0.87	0.90	0.69	0.75
FFA(24:0)	ME189101	1.39	1.27	0.55	1.41	0.84	0.63
PA 34:1; [M-H]-@5.79	ME189107	1.97	0.93	0.80	1.62	0.31	0.34
PA 36:2; [M-H]-@5.82	ME189109	1.86	1.40	0.33	1.82	0.44	0.29
FFA(22:2)	ME189099	0.65	0.33	0.48	0.31	1.81	2.21
FFA(22:3)	ME189100	0.60	0.27	0.40	0.26	1.91	2.31
FFA(18:2)	ME189092	0.53	0.28	0.51	0.28	1.97	2.18
FFA(20:2)	ME189095	0.58	0.26	0.53	0.25	1.91	2.23
FFA(24:3)	ME189104	0.90	0.34	0.47	0.30	1.29	2.47
FFA(20:1)	ME189094	0.99	0.39	0.50	0.38	1.33	2.21
FFA(24:2)	ME189103	1.06	0.47	0.50	0.47	1.14	2.18
plasmenyl-PE 36:3; [M-H]-@7.12	ME189248	0.66	0.45	1.33	0.36	0.79	2.23
plasmenyl-PE 38:3; [M-H]-@7.56	ME189252	0.55	0.32	1.61	0.27	0.64	2.39
PI 38:5; [M-H]-@5.45	ME189230	1.01	0.80	0.88	0.61	1.39	1.24
PE 39:6; [M-H]-@6.63	ME189191	0.83	0.53	1.06	0.47	1.47	1.49
PI 36:2; [M-H]-@6.01	ME189227	0.76	0.55	0.94	0.52	1.71	1.37
plasmenyl-PE 36:5; [M-H]-@6.31	ME189250	1.03	0.50	1.18	0.54	1.39	1.18
plasmenyl-PE 42:6; [M-H]-@7.74	ME189260	1.18	0.58	1.12	0.45	1.35	1.19
FFA(16:0)	ME189089	0.79	0.56	1.13	0.53	1.52	1.32
FFA(18:0)	ME189090	0.80	0.57	1.14	0.55	1.53	1.27
FFA(22:0)	ME189097	0.92	0.71	1.03	0.63	1.41	1.20
PC 36:2; [M-Ac-H]-@6.76	ME189135	0.88	0.59	1.12	0.61	1.48	1.18
PE 34:1; [M-H]-@6.85	ME189174	0.94	0.59	1.11	0.59	1.49	1.16
PE 40:8; [M-H]-@6.00	ME189194	0.82	0.51	1.20	0.44	1.67	1.19
plasmenyl-PE 36:4; [M-H]-@6.64	ME189249	0.99	0.58	1.17	0.46	1.55	1.12
PC 38:7; [M-Ac-H]-@5.62	ME189149	1.00	0.69	0.86	0.42	2.00	0.93
plasmenyl-PE 38:5; [M-H]-@6.68	ME189253	1.09	0.67	0.96	0.52	1.70	0.95
plasmenyl-PE 38:6; [M-H]-@6.59	ME189254	1.18	0.63	0.83	0.53	1.78	0.93
PC 31:1; [M-Ac-H]-@5.70	ME189118	0.86	0.49	1.03	0.51	1.82	1.11
PC 40:8; [M-Ac-H]-@5.77	ME189157	0.78	0.63	0.78	0.45	1.99	1.24
FFA(24:1)	ME189102	1.06	0.74	0.60	0.72	1.24	1.55
FFA(18:1)	ME189091	0.80	0.45	0.55	0.47	1.93	1.61
FFA(20:4) Arachidonic acid	ME189096	0.81	0.47	0.70	0.42	1.68	1.73
FFA(22:1)	ME189098	0.87	0.49	0.61	0.51	1.56	1.78
PC 28:0; [M-Ac-H]-@5.19	ME189111	0.71	0.38	1.34	0.36	1.43	1.57
PS 40:7; [M-H]-@5.41	ME189241	0.76	0.42	1.34	0.46	1.35	1.47
PC 29:0; [M-Ac-H]-@5.48	ME189113	0.56	0.39	1.22	0.34	1.51	1.77
PC 33:2; [M-Ac-H]-@5.95	ME189125	0.69	0.38	1.15	0.41	1.56	1.60
PC 31:0; [M-Ac-H]-@6.15	ME189117	0.70	0.44	1.16	0.47	1.33	1.72
PC 32:3; [M-Ac-H]-@5.28	ME189122	0.72	0.50	1.19	0.39	1.41	1.61
PE 31:0; [M-H]-@6.28	ME189168	0.85	0.42	0.83	0.67	1.06	1.98
PE 37:1; [M-H]-@7.58	ME189184	0.93	0.55	1.08	0.57	0.94	1.78
PI 38:3; [M-H]-@6.32	ME189228	0.74	0.67	1.01	0.55	1.08	1.83
PS 38:5; [M-H]-@5.52	ME189238	0.86	0.51	1.15	0.53	1.21	1.58
PC 33:0; [M-Ac-H]-@6.74	ME189123	0.84	0.67	1.08	0.56	1.13	1.61
PC 37:2; [M-Ac-H]-@7.11	ME189141	0.93	0.58	1.13	0.51	1.09	1.63
PC 40:2; [M-Ac-H]-@7.86	ME189152	0.92	0.59	1.09	0.60	1.10	1.56
PE 42:8; [M-H]-@6.59	ME189199	1.03	0.50	1.18	0.53	1.13	1.46
PC 37:1; [M-Ac-H]-@7.44	ME189140	0.98	0.55	1.11	0.56	1.20	1.44
PE 35:2; [M-H]-@6.67	ME189179	0.96	0.56	1.12	0.54	1.27	1.41
PC 34:1; [M-Ac-H]-@6.62	ME189126	0.92	0.57	1.25	0.58	1.27	1.27
PC 40:7; [M-Ac-H]-@6.20	ME189156	0.95	0.63	1.27	0.51	1.24	1.28
PC 28:1; [M-Ac-H]-@4.66	ME189112	0.87	0.39	1.36	0.53	1.24	1.42
PE 30:0; [M-H]-@6.04	ME189166	0.88	0.56	1.28	0.52	1.21	1.40
PC 32:0; [M-Ac-H]-@6.53	ME189119	0.87	0.52	1.22	0.51	1.23	1.49
PC 35:1; [M-Ac-H]-@6.84	ME189131	0.80	0.54	1.24	0.55	1.28	1.43
plasmenyl-PE 32:1; [M-H]-@6.61	ME189245	1.03	0.70	1.40	0.51	1.07	1.19
PC 34:2; [M-Ac-H]-@6.21	ME189127	0.86	0.62	1.31	0.58	1.14	1.36
PE 32:1; [M-H]-@6.24	ME189171	0.85	0.64	1.38	0.57	1.05	1.38
PE 36:0; [M-H]-@7.83	ME189181	0.94	0.66	1.27	0.56	1.03	1.44
PC 35:2; [M-Ac-H]-@6.48	ME189132	1.01	0.63	1.21	0.60	0.99	1.45
PS 34:1; [M-H]-@5.94	ME189233	0.98	0.68	1.20	0.59	0.97	1.47
lysoPE 20:4; [M-H]-@1.28	ME189243	1.02	0.67	1.14	0.62	1.07	1.36
FFA(20:0)	ME189093	0.98	0.61	1.26	0.63	1.05	1.33
lysoPE 18:0; [M-H]-@2.49	ME189242	0.96	0.65	1.21	0.67	1.02	1.38
PC 40:6; [M-Ac-H]-@6.69	ME189155	0.99	0.71	1.35	0.60	0.93	1.32
PG 36:1; [M-H]-@6.59	ME189205	0.95	0.75	1.21	0.70	0.98	1.33
PG 36:3; [M-H]-@5.34	ME189207	0.94	0.74	1.26	0.63	1.00	1.33
CL 70:5; [M-2H](2-)@9.29	ME189087	1.06	0.81	1.00	0.75	0.77	1.54
PG 38:4; [M-H]-@5.53	ME189212	1.04	0.83	1.21	0.66	0.70	1.51
PG 44:10; [M-H]-@5.44	ME189224	1.28	0.59	1.02	0.63	0.97	1.38
PI 40:5; [M-H]-@6.03	ME189231	1.00	0.74	0.96	0.56	1.04	1.61
PA 34:2; [M-H]-@6.23	ME189108	1.12	0.52	1.12	0.59	1.00	1.49
CL 68:4; [M-2H](2-)@9.23	ME189084	0.99	0.69	1.15	0.70	0.92	1.45
PC 36:6; [M-Ac-H]-@5.36	ME189139	1.03	0.73	1.15	0.57	0.92	1.52
PS 38:4; [M-H]-@6.05	ME189237	0.98	0.71	1.08	0.64	0.95	1.55
PS 36:4; [M-H]-@5.34	ME189235	1.07	0.62	1.02	0.61	0.91	1.64
CL 70:4; [M-2H](2-)@9.46	ME189086	1.09	0.61	0.97	0.71	0.95	1.54
PE 35:1; [M-H]-@7.05	ME189178	1.09	0.63	1.07	0.66	0.92	1.51
PC 30:2; [M-Ac-H]-@5.02	ME189116	1.04	0.39	1.28	0.40	1.04	1.65
PC 26:0; [M-Ac-H]-@4.47	ME189110	0.91	0.34	1.39	0.45	1.13	1.55
plasmenyl-PE 40:5; [M-H]-@7.50	ME189257	0.93	0.36	1.45	0.47	1.07	1.50
PC 38:3; [M-Ac-H]-@7.00	ME189146	0.84	0.38	1.60	0.43	1.02	1.51
PS 40:6; [M-H]-@5.94	ME189240	0.86	0.49	1.50	0.42	0.97	1.60
PC 37:4; [M-Ac-H]-@6.43	ME189143	0.78	0.53	1.23	0.53	0.96	1.81
PE 31:1; [M-H]-@6.00	ME189169	0.77	0.50	1.16	0.53	1.02	1.86
PC 36:3; [M-Ac-H]-@6.42	ME189136	0.73	0.55	1.34	0.50	1.03	1.69
PE 42:4; [M-H]-@8.01	ME189197	0.71	0.50	1.32	0.49	1.00	1.82
PS 40:4; [M-H]-@6.44	ME189239	0.73	0.52	1.27	0.54	1.02	1.76
PE 36:3; [M-H]-@6.60	ME189182	0.73	0.52	1.43	0.50	1.07	1.58
PC 32:2; [M-Ac-H]-@5.59	ME189121	0.79	0.55	1.31	0.53	1.09	1.59
PC 34:3; [M-Ac-H]-@5.88	ME189128	0.69	0.57	1.29	0.55	1.16	1.59
PC 39:6; [M-Ac-H]-@6.30	ME189150	0.77	0.45	1.25	0.46	1.15	1.73
PC 30:1; [M-Ac-H]-@5.43	ME189115	0.69	0.49	1.31	0.47	1.26	1.61
PE 37:4; [M-H]-@6.65	ME189185	0.74	0.50	1.29	0.46	1.24	1.61
PS 38:3; [M-H]-@6.42	ME189236	0.82	0.62	1.26	0.64	0.86	1.68
PC 30:0; [M-Ac-H]-@5.91	ME189114	0.91	0.55	1.34	0.48	0.95	1.62
PE 33:2; [M-H]-@6.03	ME189173	0.83	0.56	1.32	0.57	0.93	1.65
PC 32:1; [M-Ac-H]-@6.05	ME189120	0.86	0.60	1.36	0.58	0.95	1.52
PC 36:4; [M-Ac-H]-@6.10	ME189137	0.92	0.61	1.38	0.57	0.84	1.56
PE 30:1; [M-H]-@5.56	ME189167	0.89	0.48	1.60	0.51	0.72	1.63
plasmenyl-PE 34:2; [M-H]-@6.70	ME189246	0.84	0.45	1.42	0.59	0.78	1.74
PE 38:3; [M-H]-@7.18	ME189187	0.66	0.65	1.48	0.61	0.70	1.79
PE 34:3; [M-H]-@6.01	ME189175	0.68	0.50	1.61	0.43	0.93	1.69
PE 34:4; [M-H]-@5.63	ME189176	0.70	0.50	1.66	0.42	0.88	1.68
PE 35:4; [M-H]-@6.06	ME189180	0.67	0.43	1.40	0.41	0.95	1.95
plasmenyl-PE 40:3; [M-H]-@8.08	ME189255	0.63	0.45	1.55	0.36	0.93	1.89
plasmenyl-PE 34:3; [M-H]-@6.31	ME189247	0.82	0.61	1.33	0.87	0.88	1.36
PS 34:2; [M-H]-@5.36	ME189234	0.87	0.58	1.38	1.04	0.60	1.39
PE 39:4; [M-H]-@7.17	ME189190	1.35	0.53	1.10	0.62	0.61	1.63
PC 35:3; [M-Ac-H]-@6.30	ME189133	1.12	0.53	1.46	0.55	0.56	1.62
PE 36:6; [M-H]-@5.55	ME189183	1.27	0.45	1.46	0.46	0.57	1.61
PE 40:2; [M-H]-@7.98	ME189193	1.19	0.35	1.33	0.46	0.76	1.68
PC 38:2; [M-Ac-H]-@7.33	ME189145	1.16	0.49	1.28	0.62	0.69	1.60
PC 38:4; [M-Ac-H]-@6.68	ME189147	1.06	0.55	1.36	0.57	0.68	1.63
PC 33:1; [M-Ac-H]-@6.27	ME189124	1.06	0.51	1.16	0.63	0.83	1.64
PE 40:1; [M-H]-@8.41	ME189192	1.01	0.43	1.31	0.54	0.81	1.71
PC 38:1; [M-Ac-H]-@7.77	ME189144	1.32	0.58	1.28	0.66	0.61	1.41
PC 36:1; [M-Ac-H]-@7.24	ME189134	1.35	0.52	1.40	0.64	0.58	1.36
PE 44:4; [M-H]-@8.53	ME189200	1.36	0.55	1.34	0.63	0.60	1.37
PE 33:1; [M-H]-@6.54	ME189172	1.17	0.56	1.17	0.75	0.73	1.47
PC 42:2; [M-Ac-H]-@8.35	ME189160	1.11	0.69	1.26	0.71	0.66	1.46
PC 42:3; [M-Ac-H]-@7.97	ME189161	1.05	0.64	1.29	0.70	0.65	1.53
PC 36:5; [M-Ac-H]-@5.62	ME189138	1.22	0.60	1.27	0.68	0.68	1.43
PC 38:5; [M-Ac-H]-@6.34	ME189148	1.14	0.67	1.30	0.61	0.71	1.47
PC 34:4; [M-Ac-H]-@5.58	ME189129	1.03	0.64	1.47	0.64	0.67	1.43
PC 44:3; [M-Ac-H]-@8.39	ME189165	0.96	0.50	1.42	0.71	0.73	1.53
PE 39:2; [M-H]-@7.74	ME189188	1.02	0.47	1.04	0.87	0.65	1.77
PE 39:3; [M-H]-@7.53	ME189189	1.01	0.56	1.14	0.55	0.50	2.09
plasmenyl-PE 38:2; [M-H]-@7.87	ME189251	0.91	0.61	1.21	0.49	0.58	2.07
PC 40:4; [M-Ac-H]-@7.19	ME189154	0.93	0.53	1.18	0.52	0.78	1.91
PE 42:5; [M-H]-@7.59	ME189198	0.86	0.54	1.29	0.50	0.69	1.96
PC 40:3; [M-Ac-H]-@7.54	ME189153	0.99	0.63	1.23	0.55	0.68	1.80
PG 40:5; [M-H]-@5.88	ME189216	0.98	0.72	1.24	0.53	0.70	1.75
PC 37:3; [M-Ac-H]-@6.86	ME189142	0.98	0.55	1.37	0.57	0.57	1.81
PC 42:4; [M-Ac-H]-@7.74	ME189162	1.14	0.51	1.24	0.54	0.56	1.85
PG 34:1; [M-H]-@5.84	ME189203	0.99	0.93	1.77	0.86	0.58	0.84
PG 32:2; [M-H]-@4.83	ME189201	1.17	1.10	1.35	0.93	0.54	0.94
PG 34:2; [M-H]-@5.19	ME189204	1.13	0.91	1.43	0.79	0.53	1.18
PE 42:3; [M-H]-@8.39	ME189196	0.95	1.00	1.33	0.41	1.16	1.15
CL 68:2; [M-2H](2-)@9.60	ME189083	1.17	0.91	1.24	0.84	0.89	0.92
PG 36:2; [M-H]-@5.90	ME189206	1.08	0.85	1.11	0.78	1.08	1.05
PE 32:0; [M-H]-@6.73	ME189170	1.02	0.91	1.20	0.80	1.04	0.99
PG 33:1; [M-H]-@5.66	ME189202	0.99	0.94	1.22	0.78	1.00	1.04
PI 38:4; [M-H]-@5.97	ME189229	1.20	0.77	0.90	0.79	1.07	1.19
CL 70:3; [M-2H](2-)@9.65	ME189085	1.07	0.88	0.99	0.87	1.11	1.05
CL 72:4; [M-2H](2-)@9.69	ME189088	1.16	0.86	0.92	0.89	1.02	1.09
PC 42:10; [M-Ac-H]-@5.71	ME189159	1.04	0.70	0.97	0.79	1.20	1.20
N-(hexadecanoyl)-sphinganine; [M-H]-@7.05	ME189106	1.06	0.76	1.06	0.69	1.23	1.11
PG 38:2; [M-H]-@6.28	ME189210	0.98	0.79	1.18	0.75	1.18	1.06
PG 42:7; [M-H]-@5.80	ME189221	0.89	0.95	0.99	0.78	1.13	1.24
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.82	ME189105	0.99	0.83	1.00	0.76	1.02	1.34
PS 32:1; [M-H]-@5.22	ME189232	0.94	0.90	0.94	0.81	0.98	1.39
PG 36:4; [M-H]-@5.10	ME189208	1.03	0.78	1.24	0.80	0.87	1.22
PG 38:6; [M-H]-@4.99	ME189214	1.18	0.85	1.02	0.82	0.82	1.27
PG 38:5; [M-H]-@5.28	ME189213	1.13	0.84	1.09	0.69	0.92	1.27
PG 40:8; [M-H]-@4.79	ME189219	1.19	0.78	1.06	0.76	0.90	1.23
plasmenyl-PE 40:6; [M-H]-@7.18	ME189258	1.53	0.41	1.17	0.45	1.09	1.15
plasmenyl-PE 40:4; [M-H]-@7.74	ME189256	1.39	0.45	1.26	0.43	0.81	1.48
plasmenyl-PE 42:5; [M-H]-@8.04	ME189259	1.23	0.48	1.27	0.44	1.03	1.38
lysoPE 22:6; [M-H]-@1.30	ME189244	1.61	0.62	0.73	0.72	0.90	1.30
PG 42:9; [M-H]-@5.02	ME189223	1.37	0.86	1.01	0.75	0.67	1.30
PE 42:1; [M-H]-@8.81	ME189195	1.36	0.68	1.17	0.64	0.72	1.32
PG 42:8; [M-H]-@5.39	ME189222	1.25	0.81	1.14	0.68	0.73	1.33
PC 40:1; [M-Ac-H]-@8.25	ME189151	1.27	0.64	1.28	0.80	0.60	1.29
PG 38:3; [M-H]-@5.93	ME189211	1.24	0.75	1.22	0.83	0.69	1.19
PC 35:0; [M-Ac-H]-@7.33	ME189130	1.23	0.53	1.10	0.90	0.70	1.38
PE 35:0; [M-H]-@7.49	ME189177	1.31	0.67	1.12	0.78	0.60	1.41
CL 66:4; [M-2H](2-)@8.99	ME189082	1.24	0.74	1.16	1.07	0.47	1.25
PC 42:1; [M-Ac-H]-@8.72	ME189158	1.38	0.94	1.20	0.81	0.45	1.20
PE 38:1; [M-H]-@7.88	ME189186	1.63	0.48	1.21	0.53	0.59	1.39
PG 40:7; [M-H]-@5.20	ME189218	1.63	0.68	1.14	0.72	0.69	1.03
PC 44:1; [M-Ac-H]-@9.19	ME189163	1.66	0.67	1.11	0.78	0.50	1.17
PG 38:7; [M-H]-@4.56	ME189215	1.68	0.67	1.16	0.75	0.54	1.09
PG 36:5; [M-H]-@4.75	ME189209	1.43	0.69	1.31	0.75	0.50	1.22
PG 40:6; [M-H]-@5.53	ME189217	1.53	0.73	1.18	0.65	0.59	1.23

Factors:

F1	Construct:LOC_ASO
F2	Construct:Mock
F3	Construct:pCMV6_Vector
F4	Construct:Scramble
F5	Construct:TM6SF2(E167K)
F6	Construct:TM6SF2(WT)

Data matrix